A System-Wide Population Health Value Approach to Reduce Hospitalization Among Chronic Kidney Disease Patients: an Observational Study

R. Gupta, MD, MSHPM1, S. A. Skootsky, MD2,3, K. L. Kahn, MD2, L. Chen, MS2, F. Abtin, MD4, S. Kee, MD4, S. B. Nicholas, MD, MPH, PhD5, S. Vangaia, MS2, and J. Wilson, MD5

1Department of Internal Medicine, UCD Health, Sacramento, CA, USA; 2Los Angeles, USA; 3UCLA Department of Medicine, Division of General Internal Medicine and Health Services Research, Los Angeles, CA, USA; 4UCLA Health, Los Angeles, CA, USA; 5UCLA Department of Radiology, Los Angeles, CA, USA.

BACKGROUND: Chronic kidney disease (CKD) is a leading cause of healthcare morbidity, utilization, and expenditures nationally, and caring for late-stage CKD populations is complex. Improving health system efficiency could mitigate these outcomes and, in the COVID-19 era, reduce risks of viral exposure.

OBJECTIVE: As part of a system-wide transformation to improve healthcare value among populations with high healthcare utilization and morbidity, UCLA Health evaluated a new patient-centered approach that we hypothesized would reduce inpatient utilization for CKD patients.

DESIGN: For 18 months in 2015–2016 and 12 months in 2017, we conducted an interrupted time series regression analysis to evaluate the intervention’s impact on inpatient utilization. We used internal electronic health records and claims data across six payers.

PARTICIPANTS: A total of 1442 stage 4–5 CKD patients at a large academic medical center.

INTERVENTION: Between October and December 2016, the organization implemented a Population Health Value CKD intervention for the CKD stages 4–5 population. A multispecialty leadership team risk stratified the population and identified improvement opportunities, redesigned multispecialty care coordination pathways across settings, and developed greater ambulatory infrastructure to support care needs.

MAIN MEASURES: Outcomes included utilization of hospitalizations, emergency department (ED) visits, inpatient bed days, and 30-day all-cause readmissions.

KEY RESULTS: During the 12 months following intervention implementation, the monthly estimated rate of decline for hospitalizations was 5.4% (95% CI: 3.4–7.4%), which was 3.4 percentage points faster than the 18-month pre-intervention decline of 2.0% (95% CI: 1.0–2.2%) per month (p = 0.004). Medicare CKD patients’ monthly ED visit rate of decline was 3.0% (95% CI: 1.2–4.8%) after intervention, which was 2.6 percentage points faster than the pre-intervention decline of 0.4% (95% CI: −0.8 to 1.6%) per month (p = 0.02).

CONCLUSIONS: By creating care pathways that link primary and specialty care teams across settings with increased ambulatory infrastructure, healthcare systems have potential to reduce inpatient healthcare utilization.
opportunities to its CKD population. This study documents and evaluates the system-wide intervention with the goal of reducing hospitalizations.

METHODS

Context

Several empirical analyses at UCLA identified CKD 4–5 patients as a sub-cohort with high morbidity, costs, and potential to benefit from focused interventions. For example, consistent with the literature, our findings among these patients revealed frequent hospitalizations associated with an emergent need to initiate dialysis and treat malfunctioning catheters. Additionally, consistent with national findings, 53% of CKD 4–5 patients had never had a documented nephrology evaluation, potentially missing proactive care. Given the importance of CKD stage in predicting these outcomes, the institution focused its initial PHV-CKD interventions on its attributed (Appendix—Section I) CKD 4–5 patients.

UCLA created a multispecialty leadership team who used actionable electronic health records and claims data to risk stratify and identify improvement opportunities for the entire institution’s population of CKD 4–5. The primary intervention components included redesigning proactive care coordination pathways that bridge primary and multispecialty care through a system-wide CKD care team and developing greater ambulatory infrastructure to support care needs.

Study Design

We used a multiple time series design evaluating outcomes during the pre-intervention (April 1, 2015–September 30, 2016) and post-intervention (January 1, 2017–December 31, 2017) periods, excluding the implementation period (October 1, 2016–December 31, 2016) (Fig. 1).

Setting

UCLA Health is associated with the David Geffen School of Medicine that encompasses four hospitals, 150 ambulatory clinics, and 1470 clinical faculty. In 2015, the institution participated in six accountable care (ACO) contracts and underwent primary care expansion nearly doubling the patient network. To enhance care for patients, UCLA had previously introduced primary care coordinators to facilitate patients with post-hospitalization, behavioral health, and preventive health needs. Primary care coordinators, however, recognized that they needed more time to build relationships with CKD specialty care teams (i.e., nephrology, interventional radiology) and to keep current with specialty workflows and resources. These time-consuming activities were not feasible when any single coordinator’s patient panel included only a few CKD 4–5 patients. In response to these experiences, the idea of consolidating advanced CKD patients to a dedicated CKD care coordinator emerged to facilitate reliable, rapid care coordination for CKD patients with declining kidney function.

Data Sources and Measures

CKD patient stage and clinical characteristics were defined using EPIC© electronic health records (EHR) and health plan claims data across six payers at the time of patient study entry. Patient attribution and utilization outcomes data capturing both local EHR and claims encounters were collected over the full study period (Appendix—Section I, metric definitions and validation). We analyzed four available hospital-based outcomes that were collected concurrently and were assessed to be valid and complete. These included hospitalizations, ED visits, inpatient bed days, and 30-day all-cause readmissions per 1000 patient-years. The analysis cohort included two mutually exclusive patient groups with a diagnosis of CKD 4–5. Original entrants were attributed as of April 1, 2014; new entrants were attributed between April 2, 2014, and September 30, 2016, when UCLA Health primary care was expanded by nearly 22 practices. New entrants were demographically younger, had fewer concurrent conditions, and had a lower proportion of high-risk patients (Appendix—Section II, exhibit B). Both the original entrant and new entrant patients received the intervention unless they met exclusion criteria, which included receiving a kidney transplant, exiting prior to exposure to the PHV-CKD intervention, no longer meeting the rules of the attribution model or dying prior to September 30, 2016. Exited patients were excluded from post-intervention analyses following their exit date.

Development of the PHV-CKD Intervention. Between August and September 2016, a 15-member multidisciplinary, multispecialty PHV-CKD Leadership Team was developed. Their task was to identify the prevalent needs of the CKD 4–5 population, create trackable metrics, and co-create system-wide interventions to avoid emergent hospitalizations. Care coordinators had conversations with patients to incorporate patient input.

To develop an aligned system-wide approach, UCLA housed the intervention in a centralized Office of Population Health and Accountable Care, rather than within a single clinical division. This approach supported a system-level commitment to improve care for all CKD 4–5 patients, regardless of having a pre-existing relationship with a nephrologist. To achieve these goals, the Leadership Team defined and developed three support teams: a system-wide CKD Care Team, newly structured Care Coordination Team led by a CKD Care Coordinator (CKD-CC), and PHV Data Team who developed customized measures using claims and EPIC© clinical data (Fig. 2).
Implementing the PHV-CKD Intervention. The three teams identified markers for clinical decline or need (e.g., dialysis access malfunction) and developed a CKD patient registry who could benefit from early intervention. These patients included those with recent or frequent ED visits, hospitalizations, missed clinic or dialysis visits, recent declines in renal function or weight changes, or new reports of escalating problem(s) from the system-wide CKD Care Team members.

The CKD-CC (one full-time equivalent (FTE) staffed by two coordinators) used standardized care pathways that prioritized early identification of clinical decline or need, avoided duplicate care across siloed specialties, and coordinated proactive strategies to direct patients to the most appropriate venue. Care coordinators, aware that patients found fleeting contacts with members of siloed clinical settings frustrating, helped patients to engage longitudinally with a dedicated member of the system-wide CKD Care Team to best address their problems.

To execute the care pathways, the CKD-CC worked closely with 40 unlicensed primary care coordinators (PC-CCs) who had historically focused on addressing healthcare maintenance and post-discharge follow-up, however, had limited bandwidth to coordinate care across multiple siloed specialists for CKD 4–5 patients. By building upon their experience, the CKD-CC with PC-CCs considered the urgency of patient needs, the availability of caregiver supports, existing professional relationships, and staff bandwidth as they linked patients and services (Fig. 2, staff training details).

Figure 3 highlights four scenarios (A–D) describing prevalent patterns of clinical decline or need among CKD 4–5 patients with varying avenues of presentation and engagement with the health system. The figure displays a coherent model by which proactive care coordination pathways can identify patients with clinical decline; assess patient clinical, social, and care delivery needs; and enhance the likelihood of desired outcomes.
The CKD-CC operationalized pathways by communicating with patients and leading care coordination across stakeholders to implement needed interventions. The CKD-CC reviewed the CKD registry iteratively to proactively identify clinical decline or need (Fig. 3, column 1) and then assessed patient needs through phone meetings with the patient and caregivers. She promptly consolidated relevant clinical and social service needs across the system-wide CKD Care Team to align clinical and social resources and define acute care plans (Fig. 3, column 2). The CKD-CC also scheduled nephrology and primary care appointments for goals of care conversations and dialysis initiation (Fig. 3, scenario A, column 2).

If additional clinical needs emerged, the CKD-CC engaged nephrologists and primary care clinicians. The CKD-CC and lead nephrologist were co-located to facilitate this process. If neither the primary consult nephrologist nor the primary care clinician could be reached promptly, the lead nephrologist would develop urgent care plans and determine the timing of needed follow-up.23

The CKD-CC also guided appropriate patient care to less costly ambulatory care sites (Fig. 3, column 4) and used motivational interviewing to promote self-management strategies.46 This approach substantially differed from routine practice of referring patients with clinical decline or need directly to the ED (Fig. 3, legend). The CKD-CC also monitored intervention fidelity and longitudinal outcomes to improve performance (Fig. 3, column 4).

Developing Greater Ambulatory Infrastructure to Support Care Needs. Care coordination pathways guided patients who could be cared for in ambulatory settings toward primary or specialty care clinics, dialysis centers, or their homes. A network of community resources grew to offer patients early medication management and to address social determinants of health. New ambulatory care sites and operation hours emerged so that patients could receive care in the most appropriate, least costly settings. For example, with improved access, ambulatory visits could mitigate hospitalizations when appropriate.34, 35 The institution also extended hours at an existing outpatient interventional radiology suite by staggering shifts to address catheter-related problems with fewer delays.

Based on the focus and structure of this multi-pronged intervention, we hypothesized that the PHV-CKD interventions, which prioritized ambulatory care coordination, would reduce hospitalizations and emergency department utilization among CKD 4–5 patients.

Analysis

We determined frequencies, means, medians, and IQRs of CKD 4–5 patient demographics overall, stratified by payer type (i.e., Medicare versus commercial) at the time of study entry. Comparisons between strata were performed using t tests for continuous variables, and chi-squared or Fisher’s exact tests as appropriate for categorical variables. We used an interrupted time series approach, a strong longitudinal quasi-experimental design to evaluate the impact of the PHV-CKD intervention on utilization outcomes.41, 42 All outcomes were specified as rates per 1000 patient-years to account for the number of patients in the denominator at each time period. Using negative binomial marginal models,43 we examined study outcomes monthly across the study period. Primary model terms included months since the intervention, study period (pre- versus post-intervention), and the interaction of these terms. Regression models controlled for age, gender, race, ethnicity, number of comorbidities, and pre-intervention
high-risk or high-utilizer patient status. We report estimated monthly rates of change for each outcome in the pre-intervention and post-intervention periods. We performed a sensitivity analysis to evaluate the models including the intervention period in addition to the pre- and post-intervention periods. Since results remained unchanged, we present results comparing trends in outcomes during the pre- and post-intervention periods.

We conducted sensitivity analyses to compare original versus new entrants to the study cohort to assess for bias in changes of the patient population over time. We also assessed effect modification between Medicare and other payer groups, and patients who were CKD stage 4 versus CKD stage 5 at study entry. We used SAS software, version 9.4, for all analyses.

RESULTS

We analyzed utilization outcomes during the pre- and post-intervention periods for this cohort. Figure 1 shows our analytic cohort of 1442 UCLA patients with CKD 4–5 including 748 (51.9%) patients who entered the cohort by April 1, 2014,
and 694 (48.1%) patients who entered between April 2, 2014, and September 30, 2016. CKD 4–5 patients represented the top 8.4% of per member per month expenditures within the UCLA attributed patient population. Between April 1, 2013, and September 30, 2016, across 40 practices in Los Angeles, 573,248 patients were attributed to UCLA with 292,170 (51.0%) in managed contracts. Consistent with national prevalence data, 43,898 (7.7%) patients had a diagnosis of CKD 5 (based on estimated glomerular filtration rate (eGFR) < 60 mL/min/1.73 m²), and 1507 (0.5%) had CKD 4.\(^{44}\)

At the time of study entry, there were 1084 (75.2%) CKD stage 4 and 358 (24.8%) CKD stage 5 patients; 687 (47.6%) were male. Patients had a median age of 71.9 (IQR 59.7–83.2) and four concurrent conditions (IQR 0–13) (Table 1). Medicare patients were older (p < 0.001), were more likely to be non-Hispanic (p = 0.004), and had more concurrent conditions (p < 0.001) compared with non-Medicare patients (Appendix—Section II, exhibit A). Original entrant patients were older (p < 0.001), were white or black (p < 0.001), were high utilizers (p < 0.001), and had more concurrent conditions (p < 0.001) than new entrant patients (Appendix—Section II, exhibit B).

Table 2 respectively displays results of interrupted time series regression analyses for four study outcomes: hospitalization, bed days, ED visits, and 30-day all-cause readmission. The rate of hospitalizations per 1000 patient-years declined at an estimated monthly rate of 2.0% during the pre-intervention period (95% CI: −3.2%, −0.8%). After intervention implementation, the estimated rate of decline was 5.4% (95% CI: −7.4%, −3.4%), 3.5 percentage points faster than the pre-intervention decline of 2.0% per month (95% CI: −5.8%, 1.1%; p = 0.004).

The number of inpatient bed days per 1000 patient-years declined during the pre-intervention period at an estimated rate of 4.8% per month (95% CI: −7.0%, −2.5%). After intervention implementation, the estimated rate of decline was 8.6% per month (95% CI: −12.3%, −4.7%). While not statistically significant, this was 4.0 percentage points faster than the pre-intervention rate of decline (95% CI: −8.5%, 0.7%; p = 0.10).

Monthly ED visits during the pre-intervention period declined at an estimated rate of 0.9% per month (95% CI: −2.0%, −0.1%). After intervention implementation, the estimated rate of decline for the ED visit rate was 2.7% per month (95% CI: −4.3%, −0.9%). While this was not statistically significant, it was 1.7 percentage points faster than the pre-intervention rate of decline (95% CI: −3.7%, 0.3%; p = 0.09). There was no difference in 30-day all-cause readmission trends (95% CI: −33.5, 11.8%; p = 0.26).

After stratifying the outcomes by payer, we found Medicare patients’ average ED visit rate of decline was 3.0% per month (95% CI: −4.8%, −1.2%), which was significantly faster (2.6 percentage points, 95% CI: 0.4%, 4.7%; p = 0.02) than the pre-intervention decline of 0.4% per month (95% CI: −1.6%, 0.8%). The rate of decline among non-Medicare patients across the same pre-intervention and post-intervention periods was not significant (p = 0.28, not shown). Overall, the intervention effect on monthly ED visits was significantly greater for Medicare patients compared to those with other types of insurance (p = 0.03). In contrast, we found no significant differences in outcome trends after stratifying the cohort by either original and new entry patients or by CKD stages 4–5 at baseline (not shown). Our results remained unchanged in sensitivity analyses in which we included the intervention implementation period as a further study period.

**DISCUSSION**

This evaluation is one of the first empirical analyses of a large, health system–wide population health approach for acute clinical decline of CKD 4–5 patients. UCLA implemented the PHV-CKD approach to provide timely services while reducing healthcare...
utilization. The analysis, based on an interrupted time series design, demonstrated that hospitalization rates reduced more rapidly after implementation across the study population. Monthly ED visits, but not monthly bed days or readmissions, also reduced at a significantly faster rate among Medicare-insured patients known to have high medical complexity (Table 1). We anticipated that the reduction in hospitalizations and ED visits would occur first, while we believed further inpatient-based interventions may ultimately associate with reduced length of stay and hospital readmissions. The latter outcomes would require improving clinical discharge planning (e.g., needing physical therapy evaluation or new medical equipment), inpatient care management, and social work services, which we did not specifically measure as part of our evaluation.

Previous population health approaches in primary and specialty care have demonstrated only modest, if any, reductions in inpatient utilization and expenses for patient populations requiring multispecialty care. Limitations of previous programs include (1) leadership residing within siloed specialties that limit system-wide implementation, (2) patients not completing specialty clinic visits, (3) local data constraints that limit responsiveness to patient needs, (4) unclear identification of patients most likely to benefit from interventions, (5) nebulous primary and specialty care clinical alignment, and (6) narrowly resourced ambulatory care services.

The PHV-CKD intervention accounted for various ways that patients present with clinical decline or need to rapidly link them to required care. System-wide strategies included creating a robust care coordinator network across primary and specialty care enabled by EHR tools and increased ambulatory access. There has been one similar randomized trial among CKD 4–5 patients focused in a more controlled setting of three specialty clinics and found pronounced reductions in hospitalizations and ED visits. As other health systems embarking in similar efforts, they can gain different insights from this system-wide model across a broad primary care population with CKD 4–5.

A multi-source data infrastructure facilitated care coordinators in identifying patients who met criteria for clinical decline or need and allocating resources to meet patients’ needs (e.g., extending service hours). In contrast to previously cited cost-neutral programs, the UCLA PHV-CKD intervention used empirical analyses to identify a catchment of patients who may most benefit to optimize efficiency.

The intervention aligned clinicians into a system-wide effort using care coordination pathways rather than placing care coordinators within multiple siloed specialties that function independently. Without a coordinated, team-based multispecialty approach, care teams risk delivering inconsistent, duplicative, and expensive care. While previous care management programs have relied on PC-CCS, leaders found that patients benefited from care coordination that could also span specialty and community practices. The PHV intervention, therefore, allowed system-wide care coordinators to proactively identify patients with clinical decline or need to prevent hospitalizations. This approach differs from prior studies of CKD care coordination that have focused on other quality of care outcomes more than hospitalization reduction.

Study limitations include a changing patient population over time, secular trends, measuring other outcomes of value, and generalizability. UCLA underwent an expansion over the prior 5 years and acquired additional primary care practices. In response, we added analyses comparing original versus new entry patients which found no significant differences in outcomes. There is potential that other ACO efforts such as primary care–based care coordination and behavioral health integration could have influenced measured outcomes. However, for the first time, with this new intervention, the health system focused on improving outcomes and efficiency system-wide for CKD 4–5 patients. While this is a single-site study which limits generalizability, the model rests on universal concepts including development of population approaches to meet patient needs. We focused

| Utilization outcomes per 1000 patient-years | Pre-intervention period (4/1/15–9/30/16) | Post-intervention period (1/1/17–12/31/17) | Difference (post-pre-intervention periods) |
|-------------------------------------------|------------------------------------------|------------------------------------------|-------------------------------------------|
| | Percent change per month (95% CI) | Percent change per month (95% CI) | | |
| Hospitalizations | −2.0% (−3.2%, −0.8%) | −5.4% (−7.4%, −3.4%) | −3.5% (−5.8%, −1.1%) | 0.004*** |
| All inpatient bed days | −4.8% (−7.0%, −2.5%) | −8.6% (−12.3%, −4.7%) | −4.0% (−8.5%, 0.7%) | 0.10† |
| ED visits | −0.9% (−2.0%, 0.1%) | −2.7% (−4.3%, −0.9%) | −1.7% (−3.7%, 0.3%) | 0.09* |
| 30-day all-cause readmission | 4.2% (−8.3, 18.4%) | −10.2% (−28.3%, 12.6%) | −13.8% (−33.5%, 11.8%) | 0.26 |

We analyzed the utilization data from the standpoint of an interrupted time series design, using a segmented regression modeling strategy. The model was used to estimate separate log-linear time trends in the period before, and the period after, intervention rollout. This was implemented by including in the negative binomial marginal model terms for period (pre- versus post-intervention), time (modeled log-linearly in calendar months), and their interaction. Model contrasts were used to estimate the monthly rate of change in incidence rates before and after the intervention, and the interaction term was used to test for a change in trends. In each of the regression analyses, the unit of analysis was patient-month, and the response variable was the count of the relevant utilization events. Analyses were clustered at the patient level to correct inferences for the presence of repeated measures. All utilization outcomes are adjusted for patient age, gender, race, ethnicity, high risk status, high utilizer status, and comorbid condition count. p values indicate the significance of the difference in utilization between the pre- and the post-intervention periods as *p < 0.10; **p < 0.05; ***p < 0.01. CI, confidence interval.
on four clinically relevant, valid outcomes though we recognize potentially relevant outcomes that we were unable to measure. Our analyses do not include direct cost data or reimbursement data because these data were inaccessible and incomplete. Patient satisfaction data is not included because it was anonymously collected and could not be feasibly linked to study data. We do not specifically report unnecessary inpatient utilization and ED visits as there is currently no validated measure of unnecessary inpatient utilization. Finally, the analysis lacked a comparison control group, as the intervention was implemented system-wide and logistics limited using time-shifted comparison evaluation.

Next steps include expanding secondary prevention to CKD stage 1–3 patients. We also plan to adapt this model to other high-risk sub-populations and medical centers.

**CONCLUSION**

By creating primary-specialty care pathways with increased ambulatory infrastructure, healthcare systems can enhance care coordination to address patient needs while reducing hospitalizations. These findings also suggest opportunities for policies to incentivize redesigning care for stage 4–5 CKD populations.8, 9

**Acknowledgments:** The authors would like to thank Varsenik Papazyan-Gutierrez, Neil Wenger, Connie Lee, Lily Roh, David Etashoff, and Robin Clarke for their participation with the study.

**Corresponding Author:** R. Gupta, MD, MSHPM; Los Angeles, USA (e-mail: R44.gupta@gmail.com).

**Compliance with Ethical Standards:**

**Conflict of Interest:** Dr. Gupta is a Co-Director at Costs of Care, Inc. No other disclosures to report.

**REFERENCES**

1. Civic Impulse. (2017). H.R. 2 — 114th Congress: Medicare Access and CHIP Reauthorization Act of 2015. Accessed May 9, 2020: https://www.govtrack.us/congress/bills/114/hr2.
2. Alternative Payment Model Framework and Progress Tracking (APM FPT) Working Group. (2016). Alternative Payment Model (APM) Framework: Final White Paper. Retrieved from https://hcp-lan.org/workproducts/apm-whitepaper.pdf
3. Gupta R. Collateral damage occurs when doctors and patients wear ‘Covid-19 blinders.’ SDXJ. Published May 4, 2020. Accessed May 9, 2020: https://www.statnews.com/2020/05/04/collateral-damage-occurs-when-doctors-and-patients-wear-covid-19-blinders/
4. Vanholder R, Anemans L, Brown E, Gannevoort R, Gout-Zwart JJ, Lamire N, Morton RL, Postma MJ, Tonelli M, Van Biesen W, Zocca C. Reducing the costs of chronic kidney disease while delivering quality health care: a call to action. Nature Reviews Nephrology. 2017;13:393-409.
5. S. L. Hayes, C. A. Salzberg, D. McCarthy, D. C. Radley, M. K. Abrams, T. Shah, and G. F. Anderson. High-Need, High-Cost Patients: Who Are They and How Do They Use Health Care—A Population-Based Comparison of Demographics, Health Care Use, and Expenditures, The Commonwealth Fund, August 2016.
6. Cohen S, Uberoil N. Differentials in the Concentration in the Level of Health Expenditures Across Population Subgroups in the US, 2010. Rockville, MD: Agency for Healthcare Research and Quality; 2013.
7. Hong C, Siegel A, Ferris T. Caring for High-Need, High-Cost Patients: What Makes for a Successful Care Management Program? New York, NY: Commonwealth Fund: 2014.
8. Trump, Donald J. Executive Orders: Executive Order on Advancing American Kidney Health. Published July 20, 2019. Accessed May 9, 2020: https://www.whitehouse.gov/presidential-actions/executive-order-advancing-american-kidney-health/
9. CMS.gov. HHS To Transform Care Delivery for Patients with Chronic Kidney Disease. Centers for Medicare and Medicaid Services. July 10, 2019: https://www.cms.gov/newsroom/press-releases/hhs-transform-care-delivery-patients-chronic-kidney-disease.
10. Golestanine, L. Alvarez P.J, Fund SE. McGaughey KJ. Romero A. Brennen MS, Onuigbo M. All-cause costs increase exponentially with increased chronic kidney disease stage. Am J Manag Care. 2017;23(10 Suppl);S163-S172.
11. Damien P, Lanham HJ, Parthasarathy M, Shah NL. Assessing key cost drivers associated with caring for chronic kidney disease patients. BMC Health Services Research. 2016; 16:690-700.
12. U.S. Renal Data System (2018). USRDS 2018 Annual Data Report Highlights: New Report Captures the High Burden, High Cost and Low Awareness of Kidney Disease in the United States. National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD. Accessed May 9, 2020: https://wwwUSRDS.org/adrhighlights.aspx.
13. Komenda P, Tangri N, Krajcarc E, et al. Patterns of emergency department utilization by patients on chronic dialysis: a population-based study. PLoS One. 2018;13(4):e0195523.
14. Wang, V. Vilme, H., Maciejewski, M. L & Boulware, L. E. The economic burden of chronic kidney disease and end-stage renal disease. Semin. Nephrol. 36, 319–330 (2016).
15. Collins, A. J., Foley, R. N., Gilbertson, D. T. & Chen, S. C. United States Renal Data System public health surveillance of chronic kidney disease and end-stage renal disease. Kidney Int. 2015;8(2):7–2.
16. Holley JL. Advance Care Planning in CKD/ESRD: An Evolving Process. CJASN. 2012;7(6):1036–40.
17. Collins AJ, Foley RN, Herzog C, et al. US Renal Data System 2010 annual data report. Am J Kidney Dis. 2011;57(1)(suppl 1):e1-e526.
18. Fishbane S, Agrotis S, Bellucci A, et al. Augmented Nurse Care Management in CKD Stages 4 and 5: A Randomized Trial. AJKD. 2017;70(4):498-505. https://www.asjnf.org/article/S0272-6386(17)30547-4/abstract
19. Wong SP, Hebert PL, Laundry RJ, et al. Decisions about renal replacement therapy in patients with advanced kidney disease in the US Department of Veterans Affairs, 2000-2011. Clin J Am Soc Nephrol. 2016 Sep 22: pit. C.JN.03760416.
20. Saran R, Li Y, Robinson B, et al. Renal Data System 2015 annual data report: epidemiology of kidney disease in the United States. Am J Kidney Dis. 2016;67(3)(suppl 1):S1-S434.
21. Collins AJ, Foley RN, Gilbertson DT, Chen SC. The state of chronic kidney disease, ESRD, and morbidity and mortality in the first year of dialysis. Clin J Am Soc Nephrol. 2009;4(suppl 1):S55-S51.
22. End-Stage Renal Disease in the United States. Chapter 4: Hospitalizations. United States Renal Data System. 2017; 2: 321-335.
23. Phone conversations with Lily Roh, Director of Population Health at UCLA on January 18, 2019 and James Wilson, Medical Director of UCLA Stone Center and Surgical Consultative Nephrology Service on March 29, 2019.
24. U.S. Renal Data System (2018). USRDS 2018 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States. National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD. Accessed March 10, 2019: https://www.usrds.org/2018/download/v2_c04_Hospitalization_18_usrds.pdf, Volume 2, p. 387-410.
25. U.S. Renal Data System (2018). USRDS 2018 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States. National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD. Accessed May 9, 2020: https://www.usrds.org/2018/download/v1_c02_IdentCare_18_users.pdf, Volume 1, p. 29-54.
26. Nicoll R, Robertson L, Gemmell E, et al. Models of care for chronic kidney disease: A systematic review. Nephrology. 2018;23:389-396. https://www.ncbi.nlm.nih.gov/pubmed/29160599
27. Smith ZG, McNicol L, Clark TL, Cohen AJ, Ross AL, Monteiro-JF, Dworkin LD. Medical Neighborhood Model for the Care of Chronic Kidney Disease Patients. Am J Manag Care. 2016; 44(4):308-315.
28. Lisa M. Kern et al. Fragmented Ambulatory Care and Subsequent Healthcare Utilization Among Medicare Beneficiaries. Am J Manag Care. 2018; 24(9):294-300.
